Retail traders are watching ImmunityBio (IBRX) after speculation that the stock could shift from the Russell 2000 to the Russell 1000, a potential index change that has already coincided with a 1% after-hours move.

Beyond the index speculation, ImmunityBio’s recent 7 day share price return of 8.93% sits alongside a 90 day share price decline of 9.29% and a very large year to date share price gain of 262.38%. Meanwhile, the 1 year total shareholder return of 162.37% and 3 year total shareholder return of 179.39% point to strong longer term momentum despite a weaker 5 year total shareholder return.

If you are tracking how sentiment shifts around biotech and immunotherapy, it may be worth scanning other healthcare focused AI opportunities using the 38 healthcare AI stocks.

With ImmunityBio trading at a discount to the average analyst price target and showing strong recent share price swings, the key question is whether the stock still offers value or whether the market is already pricing in future growth.

Most Popular Narrative: 46% Undervalued

Compared to the most followed fair value estimate of $13.50, ImmunityBio’s last close at $7.32 leaves a wide valuation gap that the narrative attempts to explain.

The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

Want to see what sits behind that bold fair value for ImmunityBio? The narrative leans on aggressive revenue scaling, rising margins and a rich future earnings multiple. The exact mix of assumptions may surprise you.

Result: Fair Value of $13.50 (UNDERVALUED)

However, ImmunityBio’s story still carries pressure points, including the heavy reliance on ANKTIVA and the risk that regulators or payers may slow new indications and adoption.

Next Steps

With such a mix of risks and rewards around ImmunityBio, it may be useful to act promptly and test the narrative against your own judgment by reviewing the 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond ImmunityBio?

If ImmunityBio has your attention, do not stop here. Widen your watchlist now and give yourself more options before the next potential move passes you by.

• Spot potential turnaround stories early by scanning 24 elite penny stocks with strong financials that pair low share prices with financial profiles that may be stronger than many peers.
• Strengthen the core of your portfolio by reviewing 44 high quality undervalued stocks that combine quality traits with prices below their estimated worth.
• Dial back portfolio risk by filtering for 67 resilient stocks with low risk scores that our models assess as more resilient across key financial metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.